Browse > Article
http://dx.doi.org/10.14348/molcells.2017.2291

MiR-186 Inhibited Migration of NSCLC via Targeting cdc42 and Effecting EMT Process  

Dong, Ying (Department of Radiotherapy, The Tumor Hospital of Jilin Province)
Jin, Xintian (Department of Thoracic, The Tumor Hospital of Jilin Province)
Sun, Zhiqiang (Department of Invasive Technology, The Tumor Hospital of Jilin Province)
Zhao, Yueming (Department of Oncology, The Tumor Hospital of Jilin Province)
Song, Xianjing (Department of Cardiology, The Second Hospital of Jilin University)
Publication Information
Molecules and Cells / v.40, no.3, 2017 , pp. 195-201 More about this Journal
Abstract
In this study, qRT-PCR was employed to identify that miR-186 expression level in NSCLC tissues are highly associated with lymph node metastasis. In addition, through the application of western blotting, luciferase assay and qRT-PCR, it was found that miR-186 targeted 3'UTR of cdc42 mRNA and down-regulated cdc42 protein level in a post-transcriptional manner. Transwell assay indicated that cdc42 partially reversed the effect of miR-186 mimics. Besides, miR-186 was proved to regulate EMT by influencing biomarkers of this process and cell adhesion ability. Thus, miR-186 is a potential target for NSCLC therapy. miR-186 is proposed to be one of tumor-suppressors and may serve as a therapeutic target in NSCLC treatment.
Keywords
cdc42; EMT; migration; MiR-186; NSCLC;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Jemal, A., Center, M.M., DeSantis, C., and Ward, E.M. (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19, 1893-1907.   DOI
2 Ji, W., Sun, B., and Su, C. (2017). Targeting MicroRNAs in cancer gene therapy. Genes 8, pii: E21.   DOI
3 Jikuzono, T., Kawamoto, M., Yoshitake, H., Kikuchi, K., Akasu, H., Ishikawa, H., Hirokawa, M., Miyauchi, A., Tsuchiya, S., Shimizu, K., et al. (2013). The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma. Int. J. Oncol. 42, 1858-1868.   DOI
4 Lei, G.S., Kline, H.L., Lee, C.H., Wilkes, D.S., and Zhang, C. (2016). Regulation of collagen V expression and epithelial-mesenchymal transition by miR-185 and miR-186 during idiopathic pulmonary fibrosis. Am. J. Pathol. 186, 2310-2316.   DOI
5 Liu, L., Wang, Y., Bai, R., Yang, K., and Tian, Z. (2016a). MiR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1${\alpha}$ regulation. Oncogenesis 5, e224.   DOI
6 Liu, Z., Zhang, G., Yu, W., Gao, N., and Peng, J. (2016b). miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1. Biochem. Biophys. Res. Commun. 469, 692-697.   DOI
7 Profumo, V., and Gandellini, P. (2013). MicroRNAs: cobblestones on the road to cancer metastasis. Crit. Rev. Oncogenesis 18, 341-355.   DOI
8 Sun, X.J., Liu, H., Zhang, P., Zhang, X.D., Jiang, Z.W., and Jiang, C.C. (2013). miR-10b promotes migration and invasion in nasopharyngeal carcinoma cells. Asian Pac. J. Cancer Prev. 14, 5533-5537.   DOI
9 Terzuoli, E., Donnini, S., Finetti, F., Nesi, G., Villari, D., Hanaka, H., Radmark, O., Giachetti, A., and Ziche, M. (2016). Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and -186 expression: Novel mechanism of VEGF modulation in prostate cancer. Oncotarget 7, 44350-44364.   DOI
10 Yao, Y., Zhang, X., Chen, H.P., Li, L., Xie, W., Lan, G., Zhao, Z.W., Zheng, X.L., Wang, Z.B., and Tang, C.K. (2016). MicroRNA-186 promotes macrophage lipid accumulation and secretion of proinflammatory cytokines by targeting cystathionine gamma-lyase in THP-1 macrophages. Atherosclerosis 250, 122-132.   DOI
11 Yu, X., Zhang, X., Dhakal, I.B., Beggs, M., Kadlubar, S., and Luo, D. (2012). Induction of cell proliferation and survival genes by estradiolrepressed microRNAs in breast cancer cells. BMC Cancer 12, 29.   DOI
12 Zatulovskiy, E., Tyson, R., Bretschneider, T., and Kay, R.R. (2014). Bleb-driven chemotaxis of Dictyostelium cells. J. Cell Biol. 204, 1027-1044.   DOI
13 Ridley, A.J. (2015). Rho GTPase signalling in cell migration. Curr. Opin. Cell Bio. 36, 103-112.   DOI
14 Hornberger, J., Hirsch, F.R., Li, Q., and Page, R.D. (2015). Outcome and economic implications of proteomic test-guided second- or thirdline treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial. Lung Cancer 88, 223-230.   DOI
15 Bahri, S., Wang, S., Conder, R., Choy, J., Vlachos, S., Dong, K., Merino, C., Sigrist, S., Molnar, C., Yang, X., et al. (2010). The leading edge during dorsal closure as a model for epithelial plasticity: Pak is required for recruitment of the Scribble complex and septate junction formation. Development 137, 2023-2032.   DOI
16 Ben Halima, S., Siegel, G., and Rajendran, L. (2016). miR-186 in Alzheimer's disease: a big hope for a small RNA? J. Neurochem. 137, 308-311.   DOI
17 Chou, J., Wang, B., Zheng, T., Li, X., Zheng, L., Hu, J., Zhang, Y., Xing, Y., and Xi, T. (2016). MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42. Biochem. Biophys. Res. Commun. 472, 262-269.   DOI
18 de Marinis, F., and Grossi, F. (2008). Clinical evidence for secondand third-line treatment options in advanced non-small cell lung cancer. Oncologist 13 Suppl 1, 14-20.
19 Etienne-Manneville, S. (2004). Cdc42--the centre of polarity. J. Cell Sci. 117, 1291-1300.   DOI